hsa-mir-199b: Hsa-mir-199b is a miRNA that has been found to be strongly enriched for ECM and collagen terms, along with hsa-miR-152 and hsa-miR-145 [PMC3404966]. It has also been reported as a HPV core miRNA in clinical samples of head and neck squamous cell carcinoma (HNSC) and cervical squamous cell carcinoma (CESC) [PMC7794682]. Hsa-mir-199b has been investigated in relation to major depressive disorder (MDD), as its expression was compared in the blood samples of healthy individuals and MDD patients [PMC6435510]. It was found to show a significant difference between the two groups, suggesting its potential involvement in the molecular mechanisms of MDD [PMC6435510]. In individuals with obstructive sleep apnea (OSA), the circulating concentrations of hsa-mir-199b were found to be decreased after adjustment for BMI and age [PMC6748919]. Hsa-mir-199b has also been associated with overall survival (OS) in patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP therapy [PMC8745130]. It is orthologous to mmu-mir-199b, which is its mouse ortholog [PMC2632650]. Hsa-mir-199b has also been identified as differentially expressed in blood stem cells treated with plerixafor and granulocyte colony-stimulating factor, suggesting its involvement in stem cell regulation [PMC5206712]. Additionally, it has been reported to be associated with survival time in patients with hepatocellular carcinoma (HCC) [PMC6538694]. Hsa-mir-199b is part of the hsa-miR-199 family, which includes two other stem-loops: hsa-miR-199a-1 and hsa-miR-199a-2 [PMC8657878]. It has been found to be upregulated in patients with severe and/or recurrent herpes simplex virus (HSV) infection [PMC7931645]. Hsa-mir-199b has also been implicated in the regulation of VEGF expression through its interaction with the VEGFA gene [PMC5325536].